139 related articles for article (PubMed ID: 20827322)
21. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
Musquera M; Fleshner NE; Finelli A; Zlotta AR
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
[TBL] [Abstract][Full Text] [Related]
22. Dutasteride for the treatment of benign prostatic hyperplasia.
Wu C; Kapoor A
Expert Opin Pharmacother; 2013 Jul; 14(10):1399-408. PubMed ID: 23750593
[TBL] [Abstract][Full Text] [Related]
23. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
Bartsch G; Rittmaster RS; Klocker H
Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
[TBL] [Abstract][Full Text] [Related]
24. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
Debruyne F; Barkin J; van Erps P; Reis M; Tammela TL; Roehrborn C;
Eur Urol; 2004 Oct; 46(4):488-94; discussion 495. PubMed ID: 15363566
[TBL] [Abstract][Full Text] [Related]
26. Purple rice extract inhibits testosterone-induced rat prostatic hyperplasia and growth of human prostate cancer cell line by reduction of androgen receptor activation.
Kiriya C; Yeewa R; Khanaree C; Chewonarin T
J Food Biochem; 2019 Sep; 43(9):e12987. PubMed ID: 31489669
[TBL] [Abstract][Full Text] [Related]
27. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
[TBL] [Abstract][Full Text] [Related]
28. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride.
Schmidt LJ; Ballman KV; Tindall DJ
Prostate; 2007 Jul; 67(10):1111-20. PubMed ID: 17477363
[TBL] [Abstract][Full Text] [Related]
30. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction.
Traish A; Haider KS; Doros G; Haider A
Horm Mol Biol Clin Investig; 2017 Jun; 30(3):. PubMed ID: 28632494
[TBL] [Abstract][Full Text] [Related]
31. [Dutasteride: main results in the treatment of benign prostatic hyperplasia].
Le-Coent R
Ann Urol (Paris); 2004 Dec; 38 Suppl 2():S62-6. PubMed ID: 15651494
[TBL] [Abstract][Full Text] [Related]
32. Dutasteride in men receiving testosterone therapy: a randomised, double-blind study.
Kacker R; Harisaran V; Given L; Miner M; Rittmaster R; Morgentaler A
Andrologia; 2015 Mar; 47(2):148-52. PubMed ID: 24499051
[TBL] [Abstract][Full Text] [Related]
33. Growth of LAPC4 prostate cancer xenograft tumor is insensitive to 5α-reductase inhibitor dutasteride.
Garcia RR; Masoodi KZ; Pascal LE; Nelson JB; Wang Z
Am J Clin Exp Urol; 2014; 2(1):82-91. PubMed ID: 25374909
[TBL] [Abstract][Full Text] [Related]
34. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
[TBL] [Abstract][Full Text] [Related]
35. Opposing Effects of Cyclooxygenase-2 (COX-2) on Estrogen Receptor β (ERβ) Response to 5α-Reductase Inhibition in Prostate Epithelial Cells.
Liu TT; Grubisha MJ; Frahm KA; Wendell SG; Liu J; Ricke WA; Auchus RJ; DeFranco DB
J Biol Chem; 2016 Jul; 291(28):14747-60. PubMed ID: 27226548
[TBL] [Abstract][Full Text] [Related]
36. Dutasteride: a potent dual inhibitor of 5-alpha-reductase for benign prostatic hyperplasia.
Rabasseda X
Drugs Today (Barc); 2004 Aug; 40(8):649-61. PubMed ID: 15510237
[TBL] [Abstract][Full Text] [Related]
37. Effects of dutasteride on serum free-testosterone and clinical significance of testosterone changes.
Enatsu N; Miyake H; Haraguchi T; Chiba K; Fujisawa M
Andrologia; 2016 Dec; 48(10):1195-1201. PubMed ID: 26952737
[TBL] [Abstract][Full Text] [Related]
38. [Add-on effect of dutasteride in patients with benign prostatic hyperplasia treated with alpha blocker : its effect on overactive bladder].
Wada N; Hashidume K; Tamaki G; Kita M; Iwata T; Matsumoto S; Kakizaki H
Hinyokika Kiyo; 2012 Sep; 58(9):475-80. PubMed ID: 23070385
[TBL] [Abstract][Full Text] [Related]
39. Cynanchum wilfordii Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating 5α-Reductase and Androgen Receptor Activities in a Rat Model.
Lee G; Shin J; Choi H; Jo A; Pan S; Bae D; Lee Y; Choi C
Nutrients; 2017 Sep; 9(10):. PubMed ID: 28953224
[TBL] [Abstract][Full Text] [Related]
40. Dutasteride: a new 5-alpha reductase inhibitor for men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Brown CT; Nuttall MC
Int J Clin Pract; 2003 Oct; 57(8):705-9. PubMed ID: 14627182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
